HHS Secretary Kennedy Jr. and FDA Chief Announce Administration Plans to Lower U.S. Drug Prices

The Trump administration, with Health and Human Services Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, and CMS Administrator Mehmet Oz, is actively pursuing plans to lower prescription drug prices for Americans. A key initiative is TrumpRx.com, an online platform designed to guide consumers to more affordable medications, part of the administration's "Most Favored Nation" pricing strategy. This plan has prompted major pharmaceutical companies like Pfizer and AstraZeneca to agree to sell their products at the lowest prices offered in other developed countries and to establish direct-to-consumer sales channels. Despite some skepticism rooted in concerns about government programs like the Section 340B drug pricing program that have historically had mixed results, the administration emphasizes legislative and policy efforts aimed at reducing drug costs. These moves represent notable achievements in the administration's first year, addressing the long-standing issue of high medication expenses. The administration's efforts were highlighted in a press conference held on October 29, 2025, detailing these new policies and programs.